Allopurinol and global left myocardial function in heart failure patients

Journal of Cardiovascular Disease Research

Volumn 1, Issue 4, 2010, Pages 191-195

  Nasr, Gamela ^a   Maurice, Cherine ^b  

^a Suez Canal University Faculty of Medicine   (Egypt)

^b SUEZ CANAL UNIVERSITY   (Egypt)

Author keywords

Allopurinol; congestive heart failure; Tei index; uric acid

Indexed keywords

ALLOPURINOL; PLACEBO; URIC ACID;

ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DIASTOLE; DOPPLER ECHOCARDIOGRAPHY; HEART FAILURE; HEART FUNCTION; HEART PERFORMANCE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLE; SYSTOLIC DYSFUNCTION; TREATMENT RESPONSE; URIC ACID BLOOD LEVEL;

EID: 79952970484     PISSN: 09753583     EISSN: 09762833     Source Type: Journal    
DOI: 10.4103/0975-3583.74262     Document Type: Article

References (24)

1. Wang JG, Staessen JA, Fagard RH, Birkenhager WH, Gong L, Liu L. Prognostic signifi cance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. Hypertension 2001;37:1069-74. (Pubitemid 32304006)
2. Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: Molecular mechanisms and pathophysiological implications. J Physiol 2004;555:589-606. (Pubitemid 38404582)
3. Godber BL, Schwarz G, Mendel RR, Lowe DJ, Bray RC, Eisenthal R, et al. Molecular characterization of human xanthine oxidoreductase: The enzyme is grossly defi cient in molybdenum and substantially defi cient in iron-sulphur centres. Biochem J 2005;388:501-8. (Pubitemid 40839927)
4. Mellin V, Isabelle M, Oudot A, Vergely-Vandriesse C, Monteil C, Di Meglio B, et al. Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure. Eur Heart J 2005;26:1544-50. (Pubitemid 41373497)
5. Tei C. New non-invasive index for combined systolic and diastolic ventricular function. J Cardiol 1995;26:135-6.
6. Dujardin KS, Tei C, Yeo TC, Hodge DO, Rossi A, Seward JB. New index of combined systolic and diastolic myocardial performance: A simple and reproducible measure of cardiac function-a study in normals and dilated cardiomyopathy. J Cardiol 1995;26:357-66. (Pubitemid 26011184)
7. Tei C, Nishimura RA, Seward JB, Tajik AJ. Noninvasive Doppler-derived myocardial performance index: Correlation with simultaneus measurements of cardiac catheterization easurements. J Am Soc Echocardiogr 1997; 10:169-78. (Pubitemid 127789844)
8. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man: Anatomic validation of the method. Circulation 1977;55:613-8. (Pubitemid 8066109)
9. Dujardin KS, Tei C, Yeo TC, Hodge DO, Rossi A, Seward JB. Prognostic value of a Doppler index combining systolic and diastolic performance in dilated: Cardiomyopathy. Am J Cardiol 1998;82:1071-6. (Pubitemid 28507090)
10. Litwin SE, Katz SE, Morgan JP, Douglas PS. Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. Circulation 1994;89:345-54. (Pubitemid 24026509)
11. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction: Experimental observations and clinical implications. Circulation 1990;81:1161-72. (Pubitemid 20119612)
12. Swedberg K, Kjekshus J, Snapinn S. Long-term survival in severe heart failure in patients treated with enalapril: Ten year follow-up of CONSENSUS I. Eur Heart J 1999;20:136-9. (Pubitemid 29048084)
13. Swedberg K, Kjekshus J. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). Am J Cardiol 1988;62:60A-6A.
14. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
15. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17. (Pubitemid 29407370)
16. Alderman M, Aiyer KJ. Uric acid: Role in cardiovascular disease and effects of losartan. Curr Med Res Opin 2004;20:369-79. (Pubitemid 38339177)
17. Freudenberger RS, Schwarz RP Jr, Brown J, Moore A, Mann D, Givertz MM, et al. Rationale, design and organisation of an effi cacy and safety study of oxypurinol added to standard therapy in patients with NYHA class IIIIV congestive heart failure. Expert Opin Investig Drugs 2004;13:1509-16. (Pubitemid 39530203)
18. Cappola TP, Kass DA, Nelson GS, Berger RD, Rosas GO, Kobeissi ZA, et al. Allopurinol improves myocardial effi ciency in patients with idiopathic dilated cardiomyopathy. Circulation 2001;104:2407-11. (Pubitemid 33108372)
19. Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, Reaveley DA, et al. Effects of xanthine oxidase inhibition with allopurinol onendothelial function and peripheral blood fl ow in hyperuricemic patients with chronic heart failure: Results from 2 placebo-controlled studies. Circulation 2002;105:2619-24. (Pubitemid 34596038)
20. Joshua MH, Brian M, Joanne B, Charles F Jr, Ronald F, Wilson SC, et al. Impact of Oxypurinol in patients with symptomatic heart failure: Results of the OPT-CHF investigators. J Am Coll Cardiol 2008;51;2301-9.
21. Landmesser U, Spiekermann S, Preuss C, Sorrentino S, Fischer D, Manes C, et al. Angiotensin II induces endothelial xanthine oxidase activation. Role for endothelial dysfunction in patients with coronary disease. Arterioscler Thromb Vasc Biol 2007;27:943-8. (Pubitemid 46606729)
22. Doerries C, Grote K, Hilfiker-Kleiner D, Luchtefeld M, Schaefer A, Holland SM, et al. Critical role of NAD(P)H oxidase subunit p47(phox) for left ventricular remodeling/ dysfunction and survival after myocardial infarction. Circ Res 2007;100:894-903. (Pubitemid 46555695)
23. Alderman MH. Uric acid and cardiovascular risk. Curr Opin Pharmacol 2002;2:126-30. (Pubitemid 34296441)
24. Engberding N, Spiekermann S, Schaefer A, Heineke A, Wiencke A, Müller M, et al. Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: A new action for an old drug? Circulation 2004;110:2175-9. (Pubitemid 39372497)